Table 4. Multivariate analyses for treated patients with 1 molecular aberration (N = 291).

	ORa	95% CI	P
Response
Matched therapy (vs. nonmatched)	6.33b	2.65–15.13	<0.001
Lactate dehydrogenase ≤ 618 IU/L (vs. > 618 IU/L)	2.16	1.02–.60	0.045
TTF	HRc
Matched therapy (vs. nonmatched)	0.42d	0.32–0.55	<0.0001
Albumin ≥ 3.5 g/dL (vs. < 3.5)	0.45	0.29–0.68	<0.0001
Platelet count ≤ 440 × 109/L (vs. > 440)	0.34	0.18–0.65	0.001
Metastatic sites ≤ 2 (vs. >2)	0.68	0.53–0.88	0.003
Lactate dehydrogenase < 618 IU/L (vs. > 618)	0.79	0.60–1.03	0.076
Survival	HRc
Platelet count ≤ 440 × 109/L (vs. > 440 × 109/L)	0.21	0.11–0.42	<0.0001
Lactate dehydrogenase ≤ 618 IU/L (vs. > 618 IU/L)	0.56	0.40–0.77	<0.0001
Number of metastatic sites ≤ 2	0.65	0.47–0.89	0.008
Albumin ≥ 3.5 g/dL (vs. < 3.5)	0.40	0.24–0.65	0.009
Matched therapy (vs. nonmatched)	0.73e	0.53–1.01	0.06

^a0R (>1 is associated with higher response)

^bOR in univariate logistic model for response = 6.72 (P < 0.0001)

^cHR (<1 is associated with longer TTF or survival)

^dHR in univariate Cox model for TTF = 0.43 (P < 0.0001)

^eHR in univariate Cox model for survival = 0.68 (P = 0.019)